{name}
{subtitle}
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~31 mi. (Donostia / San Sebastián, Spain, +137 more cities)
facility
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1258)
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~52 mi. (Pamplona, Spain, +89 more cities)
facility
Complejo Hospitalario de Navarra; Servicio de Farmacia
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +1 more drug
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~52 mi. (Pamplona, Spain, +153 more cities)
facility
Complejo Hospitalario de Navarra
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~52 mi. (Pamplona, Spain, +197 more cities)
facility
Complejo Hospitalario de Navarra /ID# 214788, +1 more facility
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug